 |
| Cynthia Lemere, PhD |
Cynthia Lemere, PhD, of the Department of Neurology, received two grants to fund her research into developing safer, more effective ways to prevent and treat Alzheimer’s disease.
A R01 grant from the National Institute on Aging (NIA) will provide $4.2 million dollars over five years for her project “Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimer’s Disease.”
A second grant from the Cure Alzheimer’s Fund will provide $476,000 over two years for her project “Do Classical Complement Activation and the Route of Administration of Anti-Amyloid Antibodies Contribute to the Vascular Side Effects Known as ARIA?”
Starting more than 20 years ago, Lemere’s lab was one of the first to investigate active vaccines targeting amyloid-beta plaques for the prevention and treatment of Alzheimer’s disease. Her current research involves non-clinical studies of antibody treatments targeting a pathogenic form of amyloid-beta protein found in Alzheimer’s disease brains, the role of the innate immune system’s complement signaling in aging and Alzheimer’s disease, and the effects of deep space radiation on brain aging and the risk of Alzheimer’s disease in preparation for NASA’s upcoming missions to the moon and Mars.
The National Institute on Aging is one of 27 institutes and centers that comprise the National Institutes of Health. It leads a broad scientific effort to understand the nature of aging and extend the healthy, active years of life. NIA is the primary federal agency supporting and conducting Alzheimer’s disease and related dementias research.
The Cure Alzheimer’s Fund is a nonprofit organization aiming to end Alzheimer’s disease. Since 2004, its focus has been providing research grants to the world’s leading scientists researching the disease. Many of its funded projects have resulted in significant breakthroughs in developing a better understanding of Alzheimer’s disease.
